Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: In one embodiment, a process captures one or more features of an initiated application transaction within an application, and applies the one or more features to one or more application-based policies. In response to determining a policy trigger for the initiated application transaction based on applying the one or more features to the one or more application-based policies, the process may then obtain a network address associated with the application. Once the process maps the particular policy trigger from the one or more application-based policies to one or more corresponding network-based policies, then the process can instruct a network controller to apply the one or more corresponding network-based policies to the network address associated with the application, causing the network controller to configure a computer network to manage network traffic associated with the network address according to the one or more corresponding network-based policies.

Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: In one embodiment, a process captures one or more features of an initiated application transaction within an application, and applies the one or more features to one or more application-based policies. In response to determining a policy trigger for the initiated application transaction based on applying the one or more features to the one or more application-based policies, the process may then obtain a network address associated with the application. Once the process maps the particular policy trigger from the one or more application-based policies to one or more corresponding network-based policies, then the process can instruct a network controller to apply the one or more corresponding network-based policies to the network address associated with the application, causing the network controller to configure a computer network to manage network traffic associated with the network address according to the one or more corresponding network-based policies.

Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3, 4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: To preserve power and increase the overall efficiency of the CPU, the platform idle driver causes the power gate controller to cut power to the idle core. Such power gating is autonomous, i.e., the operating system and the other cores are not involved. In operation, the platform idle driver first prepares the core and the power gate controller for power gating the core. The platform idle driver then triggers the power gating. The power gate controller monitors interrupts released by the interrupt controller, and if any on the released interrupts are associated with the power gated core, the power gate controller resumes dispersing power to the core.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: A method of estimating a symbol boundary for adaptive time synchronization in a communication system is presented. An embodiment of the method includes receiving a signal comprising a plurality of OFDM symbols from receiver chains. The OFDM symbols include at least a long training field (LTF) symbol. The method further includes determining a normalized correlation signal based on correlation between the received LTF symbol and a reference symbol for each of the receiver chains for different lags. Also, the method includes estimating an energy window length for the normalized correlation signal. The energy window length includes at least one of channel delay spread and a maximum cyclic shift applied to the signal. The method then includes estimating the symbol boundary associated with the received LTF symbol based on a position of peak energy of the normalized correlation signal using the estimated energy window length.

Abstract: To preserve power and increase the overall efficiency of the CPU, the platform idle driver causes the power gate controller to cut power to the idle core. Such power gating is autonomous, i.e., the operating system and the other cores are not involved. In operation, the platform idle driver first prepares the core and the power gate controller for power gating the core. The platform idle driver then triggers the power gating. The power gate controller monitors interrupts released by the interrupt controller, and if any on the released interrupts are associated with the power gated core, the power gate controller resumes dispersing power to the core.

Abstract: A method of estimating a symbol boundary for adaptive time synchronization in a communication system is presented. An embodiment of the method includes receiving a signal comprising a plurality of OFDM symbols from receiver chains. The OFDM symbols include at least a long training field (LTF) symbol. The method further includes determining a normalized correlation signal based on correlation between the received LTF symbol and a reference symbol for each of the receiver chains for different lags. Also, the method includes estimating an energy window length for the normalized correlation signal. The energy window length includes at least one of channel delay spread and a maximum cyclic shift applied to the signal. The method then includes estimating the symbol boundary associated with the received LTF symbol based on a position of peak energy of the normalized correlation signal using the estimated energy window length.

Abstract: Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.

Abstract: The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.